FY2025 · ended Dec 31, 2025 · Revenue $20.07B, +19.9% YoY · Filed Feb 17, 2026
Boston Scientific Corporation (BSX) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $20.1 billion and net income of $2.9 billion. Free cash flow was $3.7 billion. As of Sep 30, 2026 it held $609.0 million in cash and investments and $10.9 billion in total debt.
Revenue (TTM)
$21.07B
+8.9% vs year-ago TTM
Net income (TTM)
$3.49B
+25.5% vs year-ago TTM
Operating cash flow (TTM)
$4.23B
-8.5% vs year-ago TTM
Free cash flow (TTM)
$3.33B
-12.9% vs year-ago TTM
EPS (TTM)
$2.37
+26.6% vs year-ago TTM
Dividend per share
None
Shares outstanding
1.48B
+0.5% vs prior year
Net cash
$-10.30B
as of Sep 30, 2026
Operating margin
18.7%
FY 2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- BSX (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Marlborough, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 885725
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
- West Pharmaceutical Services Inc WST
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $20.1B | $16.7B | $14.2B | $12.7B | $11.9B |
| Operating income | $3.6B | $2.6B | $2.3B | $1.6B | $1.2B |
| Net income | $2.9B | $1.8B | $1.6B | $698.0M | $1.0B |
| Diluted EPS | $1.94 | $1.25 | $1.07 | $0.45 | $0.69 |
| Operating cash flow | $4.5B | $3.4B | $2.5B | $1.5B | $1.9B |
| Free cash flow | $3.7B | $2.6B | $1.8B | $938.0M | $1.3B |
| Total assets | $43.7B | $39.4B | $35.1B | $32.5B | $32.2B |
| Stockholders' equity | $24.2B | $21.8B | $19.3B | — | — |
| Cash and investments | $2.0B | $414.0M | $865.0M | $929.0M | $1.9B |
| Total debt | $11.7B | $11.2B | $9.6B | $9.3B | $9.5B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 2, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 28, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Officer or director change, Other events
|
Oct 7, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 23, 2026 | Sep 21, 2026 |
| 8-K | Current report | Sep 8, 2026 | Sep 7, 2026 |
| 8-K |
Current report
Other events
|
Aug 26, 2026 | Aug 26, 2026 |
All 1001 Boston Scientific Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.